<PAGE> 1
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13G
INFORMATION TO BE INCLUDED IN STATEMENTS FILED
PURSUANT TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS
THERETO FILED PURSUANT TO RULE 13d-2(b)
(AMENDMENT NO. ___________)*
VIROLOGIC INC.
-------------------------------------------------------------------------------
(Name of Issuer)
COMMON STOCK, $0.001 PAR VALUE PER SHARE
-------------------------------------------------------------------------------
(Title of Class of Securities)
92823 R201
-------------------------------------------------------------------------------
(CUSIP Number)
MAY 2, 2000
-------------------------------------------------------------------------------
(Date of Event Which Requires Filing of This Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule
is filed:
[ X ] Rule 13d-1(b)
[ ] Rule 13d-1(c)
[ ] Rule 13d-1(d)
<PAGE> 2
CUSIP No. 92823 R201
--------------------------------------------------------------------------------
1. Names of Reporting Persons.
I.R.S. Identification Nos. of above persons (entities only).
BB BIOTECH AG
--------------------------------------------------------------------------------
2. Check the Appropriate Box if a Member of a Group (See
Instructions)
(a)
(b)
--------------------------------------------------------------------------------
3. SEC Use Only
--------------------------------------------------------------------------------
4. Citizenship or Place of Organization
SWITZERLAND
--------------------------------------------------------------------------------
Number of 5. Sole Voting Power
Shares Bene-
ficially -0-
Owned by Each
Reporting -------------------------------------------------------------
Person With:
6. Shared Voting Power
3,804,710(1)
-------------------------------------------------------------
7. Sole Dispositive Power
-0-
-------------------------------------------------------------
8. Shared Dispositive Power
3,804,710(1)
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
9. Aggregate Amount Beneficially Owned by Each Reporting Person
3,804,710(1)
10. Check if the Aggregate Amount in Row (11) Excludes Certain shares
11. Percent of Class Represented by amount in Row (11)
19.1%
--------------------------------------------------------------------------------
12. Type of Reporting Person (See Instructions) HC, CO
--------------------------------------------------------------------------------
Page 2 of 9 pages
1. Includes 199,705 shares of Common Stock issuable upon the exercise of
warrants.
<PAGE> 3
CUSIP No. 92823 R201
--------------------------------------------------------------------------------
1. Names of Reporting Persons.
I.R.S. Identification Nos. of above persons (entities only).
BIOTECH GROWTH S.A.
--------------------------------------------------------------------------------
2. Check the Appropriate Box if a Member of a Group
(a)
(b)
--------------------------------------------------------------------------------
3. SEC Use Only
--------------------------------------------------------------------------------
4. Citizenship or Place of Organization
PANAMA
--------------------------------------------------------------------------------
Number of 5. Sole Voting Power
Shares Bene-
ficially -0-
Owned by Each
Reporting -------------------------------------------------------------
Person With:
6. Shared Voting Power
3,804,710(1)
-------------------------------------------------------------
7. Sole Dispositive Power
-0-
-------------------------------------------------------------
8. Shared Dispositive Power
3,804,710(1)
--------------------------------------------------------------------------------
9. Aggregate Amount Beneficially Owned by Each Reporting Person
3,804,710(1)
10. Check if the Aggregate Amount in Row (11) Excludes Certain shares
11. Percent of Class Represented by amount in Row (11)
19.1%
--------------------------------------------------------------------------------
12. Type of Reporting Person
CO
--------------------------------------------------------------------------------
Page 3 of 9 pages
1. Includes 199,705 shares of Common Stock issuable upon the exercise of
warrants.
<PAGE> 4
ITEM 1.
(a) Name of Issuer
VIROLOGIC INC.
(b) Address of Issuer's Principal Executive Offices
270 EAST GRAND AVE.
SAN FRANCISCO, CA 94080
ITEM 2.
(a) Name of Person Filing
BB BIOTECH AG ("BB BIOTECH")
BIOTECH GROWTH S.A. ("BIOTECH GROWTH")
(b) Address of Principal Business Office or, if none, Residence
BB BIOTECH BIOTECH GROWTH
VORDERGASSE 3 SWISS BANK TOWER
8300 SCHAFFHAUSEN REPUBLIC OF PANAMA
CH/SWITZERLAND
(c) Citizenship
SEE ITEM NO. 4 OF COVER PAGES.
(d) Title of Class of Securities
COMMON STOCK, PAR VALUE $0.001 PER SHARE
(e) CUSIP Number
92823 R201
ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO SECTIONS 240.13D-1(b) OR
240.13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:
(a) [ ] Broker or dealer registered under section 15 of the Act (15
U.S.C. 78o).
(b) [ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
(c) [ ] Insurance company as defined in section 3(a)(19) of the Act (15
U.S.C. 78c).
Page 4 of 9 pages
<PAGE> 5
(d) [ ] Investment company registered under section 8 of the Investment
Company Act of 1940 (15 U.S.C. 80a-8).
(e) [ ] An investment adviser in accordance with Section
240.13d-1(b)(1)(ii)(E);
(f) [ ] An employee benefit plan or endowment fund in accordance with
Section 240.13d-1(b)(1)(ii)(F);
(g) [ ] A parent holding company or control person in accordance with
Section 240.13d-1(b)(1)(ii)(G);
(h) [ ] A savings associations as defined in Section 3(b) of the Federal
Deposit Insurance Act (12 U.S.C. 1813);
(i) [ ] A church plan that is excluded from the definition of an
investment company under section 3(c)(14) of the Investment
Company Act of 1940 (15 U.S.C. 80a-3);
(j) [ ] Group, in accordance with Section 240.13d-1(b)(1)(ii)(J).
ITEM 4. OWNERSHIP
Provide the following information regarding the aggregate number and
percentage of the class of securities of the issuer identified in Item 1.
(a) Amount beneficially owned:
3,804,710(1)
(b) Percent of class:
19.1%
(c) Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote
-0-
(ii) Shared power to vote or to direct the vote
3,804,710(1)
(iii) Sole power to dispose or to direct the disposition of
-0-
(iv) Shared power to dispose or to direct the disposition of
3,804,710(1)
Page 5 of 9 pages
1. Includes 199,705 shares of Common Stock issuable upon the exercise of
warrants.
<PAGE> 6
ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS
If this statement is being filed to report the fact that as of the date
hereof the reporting person has ceased to be the beneficial owner of more than
five percent of the class of securities, check the following.[ ]
ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.
Not applicable.
ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE
SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY
This statement is filed jointly by BB Biotech and Biotech Growth. Biotech
Growth is a wholly-owned subsidiary of BB Biotech.
ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP
Not applicable.
ITEM 9.
Not applicable.
ITEM 10. CERTIFICATION
By signing below I certify that, to the best of my knowledge and belief,
the securities referred to above were acquired and are held in the ordinary
course of business and were not acquired and are not held for the purpose of or
with the effect of changing or influencing the control of the issuer of the
securities and were not acquired and are not held in connection with or as a
participant in any transaction having that purpose or effect.
Page 6 of 9 pages
<PAGE> 7
SIGNATURES
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
BB BIOTECH AG
Date: June 10, 2000 By: /s/ ANDERS HOVE
-------------------------
Name: ANDERS HOVE
------------------------
Title: SIGNATORY AUTHORITY
------------------------
Date: June 10, 2000 By: /s/ DUBRAVKA RACNJAK
-------------------------
Name: DUBRAVKA RACNJAK
------------------------
Title: SIGNATORY AUTHORITY
------------------------
BIOTECH GROWTH S.A.
Date: June 10, 2000 By: /s/ ANDERS HOVE
-------------------------
Name: ANDERS HOVE
------------------------
Title: SIGNATORY AUTHORITY
------------------------
Date: June 10, 2000 By: /s/ DUBRAVKA RACNJAK
-------------------------
Name: DUBRAVKA RACNJAK
------------------------
Title: SIGNATORY AUTHORITY
------------------------
Page 7 of 9 pages
<PAGE> 8
EXHIBIT INDEX
Exhibit 1: Agreement by and between BB Biotech and Biotech Growth with
respect to the filing of this disclosure statement.
Page 8 of 9 pages
<PAGE> 9
JOINT FILING AGREEMENT
We, the undersigned, hereby express our agreement that the attached
Schedule 13G (including all amendments thereto) is filed on behalf of each of
the undersigned.
BB BIOTECH AG
Date: June 12, 2000 By: /s/ Anders Hove
---------------------------
Name: Anders Hove
---------------------------
Signatory Authority
Date: June 12, 2000 By: /s/ D. Racnjak
---------------------------
Name: D. Racnjak
---------------------------
Signature Authority
BIOTECH GROWTH, S.A.
Date: June 12, 2000 By: /s/ Anders Hove
---------------------------
Name: Anders Hove
---------------------------
Signatory Authority
Date: June 12, 2000 By: /s/ D. Racnjak
---------------------------
Name: D. Racnjak
---------------------------
Signatory Authority
Page 9 of 9 pages
